Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu + pertuzumab
fam-trastuzumab deruxtecan-nxki + pertuzumab · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer (IHC 3+ or ISH-positive on an FDA-approved test).
LAMPGEN ANALYSIS
Why it matters
The approval brings a HER2-directed antibody–drug conjugate plus pertuzumab into first-line treatment of eligible HER2-positive advanced disease.
What research teams should watch
Confirm HER2 positivity and put pneumonitis reporting and cardiac surveillance into the first-line treatment workflow.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
HER2-selected breast cancerPRIMARY RECORDS